Crossmark

The End of Phase 3 Clinical Trials in Biosimilars Development?

Crossref DOI link: https://doi.org/10.1007/s40259-018-0287-0

Published Online: 2018-06-26

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Frapaise, Francois-Xavier https://orcid.org/0000-0002-9680-5457
License Information

Text and Data Mining valid from 2018-06-26
More Information

Article History

First Online: 26 June 2018

Compliance with Ethical Standards

:

: No funding was received for the preparation of this review.

: Dr Frapaise has no conflicts of interest.